Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
i7h
Britons face paying more for weight-loss jabs... to make them cheaper for Americans
Anti-obesity drug Mounjaro is set rack up sales of nearly £22bn a year by 2030. But Trump's 'America First' policies mean Britons could soon be paying more for the 'King Kong' of weight-loss jabs ...
The Motley Fool3d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...
Eli Lilly plans to expand its pipeline to address obesity-related conditions in India, says top executive
US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...
Ozempic Defendants Seek to Shave 'Tacked On' Claims From MDL Complaint
Novo Nordisk and Eli Lilly's motion to dismiss took aim at most of the counts asserted in the plaintiffs’ master long-form ...